Skip to main content
HINOVA PHARMACEUTICALS INC. logo

HINOVA PHARMACEUTICALS INC. — Investor Relations & Filings

Ticker · 688302 ISIN · CNE1000059F5 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2022-04-28 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688302

About HINOVA PHARMACEUTICALS INC.

https://www.hinovapharma.com/

Hinova Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of cancers and metabolic diseases. The company leverages its core technology platforms, including targeted protein degradation (PROTAC) and deuterium-based drug discovery, to develop a diverse pipeline of small molecule therapeutics. Its lead candidate, HC-1119 (deuterenzalutamide), is a next-generation androgen receptor antagonist currently in late-stage clinical development for metastatic castration-resistant prostate cancer. Other key programs include HP518, an orally bioavailable PROTAC degrader targeting the androgen receptor, and HP501, a selective URAT1 inhibitor designed for the treatment of hyperuricemia and gout. Hinova aims to address significant unmet medical needs through the development of high-quality, differentiated therapies for global markets.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于海创药业股份有限公司预计2022年度关联交易的核查意见
Audit Report / Information Classification · 95% confidence The document is a verification opinion from a sponsoring institution (中信证券股份有限公司) regarding the expected related-party transactions of 海创药业股份有限公司 for the year 2022. It includes details about the nature, amounts, and approval procedures of these related-party transactions, as well as the sponsor's opinion on the compliance and fairness of these transactions. The document is not a full annual or interim report, nor is it an earnings release or a regulatory filing of a different nature. It is a specialized audit or verification report related to internal controls and compliance on related-party transactions, which fits the category of an Audit Report / Information (AR). The document length is 2491 characters, which is relatively short but contains substantive content and detailed analysis, not just an announcement or certification. Therefore, the best classification is AR with high confidence. FY 2022
2022-04-28 Chinese
对外投资管理制度
Governance Information Classification · 95% confidence The document is titled '对外投资管理制度' (External Investment Management System) of 海创药业股份有限公司 (Haichuang Pharmaceutical Co., Ltd.) dated April 2022. It is a detailed internal policy document outlining the principles, approval authorities, organizational structure, management procedures, financial management, auditing, reporting requirements, and other governance aspects related to the company's external investments. It references relevant laws and regulations but does not contain financial statements, earnings data, or audit opinions. It is not a report of financial results, audit, or regulatory filing, nor is it an announcement or presentation. Instead, it is a governance and management policy document related to investment activities. Therefore, the most appropriate classification is Governance Information (CGR).
2022-04-28 Chinese
关于2022年度日常关联交易预计的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the company's expected related party transactions for the year 2022. It includes details about the nature, amounts, and approval process of these transactions, as well as opinions from independent directors and the sponsor institution. The document explicitly states that these transactions do not require shareholder meeting approval and focuses on compliance and disclosure of related party dealings. It does not contain financial statements or comprehensive financial performance data. The document length is 3427 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits best into the category of Regulatory Filings (RNS), as it is a regulatory disclosure about related party transactions without constituting a full financial report or other specific filing types.
2022-04-28 Chinese
对外担保管理制度
Governance Information Classification · 95% confidence The document is titled '海创药业股份有限公司 对外担保管理制度' which translates to 'Hai Chuang Pharmaceutical Co., Ltd. External Guarantee Management System'. It is a detailed internal policy document outlining the rules, scope, review, decision-making, contract signing, risk management, disclosure, and responsibilities related to the company's external guarantees. The document is dated April 2022 and contains no financial statements, earnings data, or regulatory filings. It is not an announcement or a report of financial results but rather a governance or management policy document. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. The content is about internal governance and management practices related to external guarantees, which aligns best with Governance Information (CGR).
2022-04-28 Chinese
海创药业公司章程
Governance Information Classification · 100% confidence The document is a detailed company charter or articles of association for 海创药业股份有限公司 (Hinova Pharmaceuticals Inc.). It includes chapters on general provisions, business scope, share issuance, share transfer, shareholders and shareholders' meetings, board of directors, senior management, supervisory board, financial accounting system, profit distribution, audit, notices, mergers, capital changes, dissolution, and amendments to the charter. It references laws and regulations governing company formation, shareholder rights, board responsibilities, and share capital management. The document is lengthy (15,000 characters) and contains no financial statements, earnings data, or audit opinions. It is not an announcement or a brief summary but a full governance document outlining the company's internal rules and governance structure. Therefore, it fits the category of Governance Information (CGR).
2022-04-10 Chinese
海创药业首次公开发行股票科创板上市公告书
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the initial public offering (IPO) and listing of a company named 海创药业股份有限公司 on the Shanghai Stock Exchange's STAR Market (科创板). It includes extensive risk disclosures, company background, clinical trial progress, financial conditions, and stock issuance details. The document references the approval from the China Securities Regulatory Commission (CSRC) and the Shanghai Stock Exchange for the IPO and listing. It is not a full annual or quarterly financial report, nor is it a transcript, audit report, or management change announcement. It is a comprehensive listing prospectus or listing announcement document, which is typically classified as a Regulatory Filing (RNS) because it is a regulatory announcement about the company's stock listing and IPO, containing detailed disclosures but not constituting a full financial report like a 10-K or IR. The document length (15,000 characters) and content confirm it is not a brief announcement or a report publication announcement. Therefore, the best fitting category is Regulatory Filings (RNS).
2022-04-10 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.